Literature DB >> 8563734

Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity.

F A Houssiau1, C Lefebvre, M Vanden Berghe, M Lambert, J P Devogelaer, J C Renauld.   

Abstract

We investigated whether serum titers of interleukin 10 (IL-10), a cytokine known to shift lymphocyte responses towards humoral immunity, reflect disease activity in systemic lupus erythematosus (SLE). Sera from 72 SLE patients, 25 RA patients and 30 healthy controls were tested for IL-10 by ELISA. Low titers of IL-10 were detected in the serum of 37.5% of SLE patients and in 24% of RA patients but in only 3% of healthy controls. Interestingly, serum IL-10 titers in SLE patients were positively correlated with the SLE Disease Activity Index (SLEDAI) and with anti-DNA antibody titers, but negatively with complement fraction C3 levels. These results indicate that serum IL-10 values reflect SLE disease activity and suggest that overexpression of IL-10 might play a pathogenic role in severe lupus disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8563734     DOI: 10.1177/096120339500400510

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  73 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

Review 2.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

3.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

4.  IVIg attenuates TLR-9 activation in B cells from SLE patients.

Authors:  Aharon Kessel; Regina Peri; Tharwat Haj; Ayelet Snir; Gleb Slobodin; Edmond Sabo; Itzhak Rosner; Yehuda Shoenfeld; Elias Toubi
Journal:  J Clin Immunol       Date:  2010-10-05       Impact factor: 8.317

5.  Interleukin-10 receptor expression and signalling were down-regulated in CD4⁺ T cells of lupus nephritis patients.

Authors:  H D Cui; Z M Qi; L L Yang; L Qi; N Zhang; X L Zhang; S Y Du; Y Jiang
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

6.  IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings.

Authors:  M Gelati; E Lamperti; A Dufour; E Corsini; E Venegoni; C Milanese; A Nespolo; A Salmaggi
Journal:  Ital J Neurol Sci       Date:  1997-08

Review 7.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

8.  IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.

Authors:  Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

Review 9.  B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases.

Authors:  William Stohl
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

Review 10.  Pathogenesis of systemic lupus erythematosus.

Authors:  C C Mok; C S Lau
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.